Pharmalink is a specialty pharma company developing high-value, global products for patients with significant unmet medical needs.

Pharmalink is focused on the development and commercialisation of its lead product candidate Nefecon, which has successfully completed a Phase 2b clinical trial as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure.

Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Pharmalink now aims to further Nefecon through Phase 3 to registration. In addition, the Company has identified other potential uses of Nefecon and will investigate opportunities for development in these other niche indications as a means to maximize value and to provide new medications for patients with unmet medical needs.

The Company is based in Stockholm, Sweden, and has a subsidiary at the Oslo Cancer Cluster, Norway, to draw on clinical development expertise in the Oslo region and to identify potential in-licensing opportunities.

News & Events
Oct 1, 2015
READ MORE...
Apr 14, 2015
READ MORE...
Mar 18, 2015
READ MORE...
Jan 21, 2015
READ MORE...